title: EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.
abstract: The epithelial cell adhesion molecule (EpCAM) is a 40-kD type I transmembrane protein that is overexpressed in human epithelial cancers and is currently the target of molecular therapy based on its overexpression at the cell surface. Recently, we and others have shown a role for EpCAM in cell signaling and carcinogenesis, and EpCAM expression seems to promote breast cancer invasion. Interleukin-8 (IL-8/CXCL-8) is an inflammatory cytokine that has recently been shown to modulate breast cancer invasion and angiogenesis. In preliminary experiments, we identified a correlation between EpCAM and IL-8 expression in primary human breast cancers. Specific ablation of EpCAM in breast cancer cell lines results in decreased IL-8 expression, and IL-8 contributes to EpCAM-dependent breast cancer invasion. Specific ablation of EpCAM is also associated with decreased NF-κB transcription factor activity, decreased phosphorylation of the NF-κB family member RELA, and increased IκBα protein expression. EpCAM modulates IL-8 expression at baseline, and following IL-1β stimulation, which is known to be a potent inducer of NF-κB in breast cancer. In functional rescue experiments, specific ablation of RELA or forced expression of the NF-κB inhibitor protein IκBα prevented EpCAM-dependent rescue of IL-8 promoter activity. These studies show for the first time that EpCAM can modulate NF-κB transcription factor activity and IL-8 expression in breast cancer and confirm the role of EpCAM signaling in modulating breast cancer invasion. Further study is required to define the molecular mechanism(s) of EpCAM signaling in breast cancer and to direct the rational development of molecular therapies targeting EpCAM.
authors: Department of Surgery, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, Missouri 63110, USA.
authors: Narendra V
authors: NV
authors: Sankpal
authors: Timothy P
authors: TP
authors: Fleming
authors: William E
authors: WE
authors: Gillanders
mesh_terms: D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000096:biosynthesis* / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D000071858:Epithelial Cell Adhesion Molecule; D005260:Female; D005786:Gene Expression Regulation; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D061986:MCF-7 Cells; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D015398:Signal Transduction
chemical_list: D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; C499379:EPCAM protein, human; D000071858:Epithelial Cell Adhesion Molecule; D016209:Interleukin-8; D016328:NF-kappa B
references: PLoS One. 2011 Mar 21;6(3):e17911
references: 21445301
references: J Immunol. 2006 Dec 1;177(11):7990-9
references: 17114472
references: Clin Cancer Res. 2004 Nov 1;10(21):7157-62
references: 15534087
references: Int J Cancer. 2007 Nov 1;121(9):1949-57
references: 17621625
references: J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):215-23
references: 14635796
references: Lancet. 1982 Apr 3;1(8275):762-5
references: 6121224
references: Cancer. 2001 Aug 1;92(3):620-8
references: 11505407
references: Clin Cancer Res. 2008 Sep 15;14(18):5849-55
references: 18794096
references: Breast Cancer Res Treat. 2004 Aug;86(3):207-13
references: 15567937
references: Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10137-42
references: 15220474
references: Oncogene. 2006 Oct 30;25(51):6817-30
references: 17072330
references: Oncogene. 2004 Aug 12;23(36):6105-14
references: 15208657
references: Trends Immunol. 2004 Feb;25(2):75-84
references: 15102366
references: Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8
references: 12917485
references: Br J Cancer. 2007 Feb 12;96(3):417-23
references: 17211480
references: J Clin Oncol. 2009 Apr 20;27(12):1926-9
references: 19273695
references: Breast Cancer Res. 2011;13(6):R124
references: 22132731
references: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references: 12829800
references: Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5
references: 15240889
references: Oncogene. 2004 Jul 29;23(34):5748-58
references: 15195135
references: Oncogene. 2007 Jan 4;26(1):1-10
references: 16799638
references: J Biol Chem. 2004 Dec 31;279(53):55633-43
references: 15489227
references: Breast Cancer Res. 2012 Oct 12;14(5):R131
references: 23062209
references: Cancer Res. 2009 Feb 1;69(3):753-7
references: 19141643
references: Breast Cancer Res Treat. 2001 Jan;65(2):101-10
references: 11261825
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: J Immunol. 2003 Mar 15;170(6):3369-76
references: 12626597
references: Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438-42
references: 286328
references: Int J Cancer. 2002 Apr 20;98(6):883-8
references: 11948467
references: Hum Pathol. 2004 Jan;35(1):122-8
references: 14745734
references: J Surg Res. 2009 Sep;156(1):50-6
references: 19524940
references: Cancer Res. 2004 Aug 15;64(16):5818-24
references: 15313925
references: J Natl Cancer Inst. 1998 May 6;90(9):691-7
references: 9586666
references: Nat Cell Biol. 2009 Feb;11(2):162-71
references: 19136966
references: Br J Cancer. 2006 Jan 16;94(1):128-35
references: 16404366
references: Oncogene. 2003 Jan 16;22(2):256-65
references: 12527894
references: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references: 11553815
references: Cancer Res. 2009 Jul 15;69(14):5627-9
references: 19584271
references: Oncogene. 2007 Jun 7;26(27):3989-97
references: 17213811
references: Clin Cancer Res. 2008 Nov 1;14(21):6735-41
references: 18980965